Skip to main content

Table 1 Eligibility criteria of included studies

From: The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review

PopulationWomen with HER2-positive breast cancer
InterventionNeoadjuvant or adjuvant treatment with subcutaneous trastuzumab
ControlNeoadjuvant or adjuvant treatment with intravenous trastuzumab
Outcomes• Efficacy (overall survival, event-free survival)
• Safety: overall risk of adverse events, serious adverse events, discontinuation because of adverse events
• Patients’ preferences
Study designRCTs, systematic reviews, and meta-analyses
  1. HER human epidermal growth factor receptor, RCT randomized controlled trial